NCT00710710 2022-05-04Open, Randomized Phase II Trial to Investigate the Efficacy and Safety of the PLK-1 Inhibitor BI 2536 in Patients With Advanced, Unresectable Pancreatic CancerBoehringer IngelheimPhase 2 Completed89 enrolled 20 charts